NBSE News and Press, NeuBase Therapeutics Inc. From 03/26/20

PITTSBURGH, March 26, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to add...

PITTSBURGH, Feb. 21, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) announced today that it received a standard notification letter dated February 20, 2020 (the “Notice”) from The Nasdaq Stock Market ...

This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking David Einhorn's Greenlight Capital Hol...

Arcturus Therapeutics (NASDAQ: ARCT ) initiated with Buy rating and $19 (70% upside) price target at Guggenheim. More news on: Arcturus Therapeutics Holdings Inc., BeyondSpring Inc., Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

NeuBase Therapeutics (NASDAQ: NBSE ): FY Non-GAAP EPS of -$0.45; GAAP EPS of -$3.26 misses by $1.98 . More news on: NeuBase Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

PITTSBURGH, Jan. 09, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies using its scalable PATrOL™ platform to address genetic diseases, to...

The genetics industry supports every other life science industry, with one contribution being the discovery of new genetic drivers of diseases. In terms of the genetic testing market, this area has grown substantially over the last few years thanks to advances made in technology ; in lin...

PITTSBURGH, Dec. 02, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that one of its core technolo...

Evercore ISI HealthCONx Conference panel discussion at 12:30 p.m. ET on December 3 rd Piper Jaffray 31st Annual Healthcare Conference presentation at 8:30 a.m. ET on December 4 th PITTSBURGH, Nov. 25, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“Neu...

NeuBase Therapeutics (NASDAQ: NBSE ) is building on a strong gain today, up 5.2% after hours as it gets an initiation at Outperform by Oppenheimer. More news on: NeuBase Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...